What is NDC 0409-2045?

0409-2045 is the product NDC for Milrinone Lactate in Dextrose, Milrinone lactate .2 mg/mL injection, solution, listed with the FDA by Hospira, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Hospira, Inc., NDC labeler code 0409. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Milrinone Lactate in Dextrose?

8 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Milrinone Lactate in Dextrose NDC 0409-2045

NDC codes

FDA NDC Directory

Product NDC (as listed)0409-2045Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00409-2045Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0409-2045-10	0040920451000409204510	10 POUCH in 1 CARTON (0409-2045-10) / 1 BAG in 1 POUCH (0409-2045-01) / 100 mL in 1 BAGMarketed from Apr 4, 2022

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Milrinone Lactate in Dextrose
Generic name (nonproprietary): milrinone lactate in dextrose
Active ingredients: Milrinone lactate — .2 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Hospira, Inc.NDC labeler code 0409
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213585
Marketing start: Apr 4, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 0409-2045_41afad76-bea1-46c5-ab31-84a54b157410SPL ID 41afad76-bea1-46c5-ab31-84a54b157410SPL set ID 5273ea17-6920-4bff-8c5b-20ea531a0423RxCUI 1791840, 1791842UNII 9K8XR81MO8
Pharmacologic class: Phosphodiesterase 3 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400409204510 followed by a unit qualifier and the quantity

Package 00409-2045-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 28, 2022.

Indications (excerpt from the label)

INDICATIONS & USAGE Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0409-2045

What is NDC 0409-2045?: 0409-2045 is the product NDC for Milrinone Lactate in Dextrose, Milrinone lactate .2 mg/mL injection, solution, listed with the FDA by Hospira, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Milrinone Lactate in Dextrose.
What is the active ingredient?: Milrinone lactate.
Who is the labeler?: Hospira, Inc., NDC labeler code 0409. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Milrinone Lactate in Dextrose?: 8 other product NDCs are listed under this name. See all Milrinone Lactate in Dextrose NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Milrinone Lactate in Dextrose NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Milrinone Lactate in Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	0409-1983	00409-1983-10
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Sagent Pharmaceuticals	25021-313	25021-0313-8225021-0313-87
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Gland Pharma Limited	68083-410	68083-0410-10
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Gland Pharma Limited	68083-411	68083-0411-10
Milrinone Lactate in Dextrose	Milrinone lactate 200 ug/mL	Injection, SolutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9718	00143-9718-10
Milrinone Lactate in Dextrose	Milrinone lactate 200 ug/mL	Injection, SolutionIntravenous	Hikma Pharmaceuticals USA Inc.	0143-9719	00143-9719-10
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Baxter Healthcare Corporation	0338-6010	00338-6010-48
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Baxter Healthcare Corporation	0338-6011	00338-6011-37

Other NDCs under ANDA 213585

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213585
Product	Strength	Form · route	Labeler	Product NDC
Milrinone Lactate in Dextrose	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Hospira, Inc.	0409-1983
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Sagent Pharmaceuticals	25021-313
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Gland Pharma Limited	68083-410
Milrinone Lactate in Dextrosemilrinone lactate	Milrinone lactate .2 mg/mL	Injection, SolutionIntravenous	Gland Pharma Limited	68083-411